Download PDF
Thromb Haemost 2007; 98(03): 685-687
DOI: 10.1160/TH07-03-0171
Letters to the Editor
Schattauer GmbH

Acquired factor V inhibitor after haematopoietic stem cell transplantation

Dragana Milojkovic
1   Department of Haematological Medicine, King’s College Hospital, London, UK
,
Raj Patel
1   Department of Haematological Medicine, King’s College Hospital, London, UK
,
Elizabeth Ford
1   Department of Haematological Medicine, King’s College Hospital, London, UK
,
Roopen Arya
1   Department of Haematological Medicine, King’s College Hospital, London, UK
,
Ghulam Mufti
1   Department of Haematological Medicine, King’s College Hospital, London, UK
› Author Affiliations
Further Information

Publication History

Received 05 March 2007

Accepted after revision 21 May 2007

Publication Date:
28 November 2017 (online)

    Permissions and Reprints

 

 

  • References

  • 1 Mann KG, Kalafatis M. Factor V: a combination of Dr Jekyll and Mr Hyde. Blood 2003; 101: 20-30.
    CrossrefPubMedGoogle Scholar
  • 2 Knobl P, Lechner K. Acquired factor V inhibitors. Baillieres Clin Haematol 1998; 11: 305-318.
    CrossrefPubMedGoogle Scholar
  • 3 Favaloro EJ, Bonar R, Duncan E. et al. RCPA QAP in Haematology Haemostasis Committee.. Identification of factor inhibitors by diagnostic haemostasis laboratories: a large multi-centre evaluation. Thromb Haemost 2006; 96: 73-78.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 4 Favaloro EJ, Posen J, Ramakrishna R. et al. Factor V inhibitors: rare or not so uncommon? A multi-laboratory investigation. Blood Coagul Fibrinolysis 2004; 15: 637-647.
    CrossrefPubMedGoogle Scholar
  • 5 Leroy-Matheron C, Mallat A, Duvoux C. et al. Inhibitor against coagulation factor V after liver transplantation. Transplantation 1999; 68: 1054-1056.
    CrossrefPubMedGoogle Scholar
  • 6 Lim ZY, Ho AY, Ingram W. et al. Outcomes of alemtuzumab- based reduced intensity conditioning stem cell transplantation using unrelated donors for myelodysplastic syndromes. Br J Haematol 2006; 135: 201-209.
    CrossrefPubMedGoogle Scholar
  • 7 Mufti GJ, Figes A, Hamblin TJ. et al. Immunological abnormalities in myelodysplastic syndromes. I. Serum immunoglobulins and autoantibodies. Br J Haematol 1986; 63: 143-147.
    CrossrefPubMedGoogle Scholar
  • 8 Castelli R, Faricciotti A, Cicuti S. et al. Acquired factor VIII inhibitor in association with myelodysplastic syndrome: report of a new case. Haematologica 2002; 87: ECR02.
    PubMedGoogle Scholar
  • 9 Klumpp TR, Block CC, Caligiuri MA. et al. Immune- mediated cytopenia following bone marrow transplantation. Case reports and review of the literature. Medicine (Baltimore) 1992; 71: 73-83.
    CrossrefPubMedGoogle Scholar
  • 10 Drobyski WR, Potluri J, Sauer D. et al. Autoimmune hemolytic anemia following T cell-depleted allogeneic bone marrow transplantation. Bone Marrow Transplant 1996; 17: 1093-1099.
    PubMedGoogle Scholar
  • 11 Scherer Y, Shoenfeld Y. Autoimmune diseases and autoimmunity post-bone marrow transplantation. Bone Marrow Transplant 1998; 22: 873-881.
    CrossrefPubMedGoogle Scholar
  • 12 Akhtari M, Raj K, Ingram W. et al. Clonal gammopathies, immune cytopenias and autoimmune thyroid dysfunction following alemtuzumab containing reduced- intensity allogeneic hematopoietic stem cell transplantation. Blood 2004 104. 1839a
    PubMedGoogle Scholar
  • 13 Lucia JF, Aguilar C. A case of an asymptomatic idiopathic inhibitor to coagulation factor V. Haemophilia 2005; 11: 178-180.
    CrossrefPubMedGoogle Scholar